Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern

Chang Yi Wang, Kao-Pin Hwang, Hui-Kai Kuo, Be-Sheng Kuo, Hope Liu, Kuo-Liang Hou, Wan-Yu Tsai, Han-Chen Chiu, Yu-Hsin Ho, Jennifer Cheng, Min-Sheng Wang, Ya-Ting Yang, Po-Yen Chang, Yea-Huei Shen, Wen-Jiun Peng
doi: https://doi.org/10.1101/2022.04.11.22272364
Chang Yi Wang
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cywang{at}unitedbiopharma.com
Kao-Pin Hwang
2Division of Infectious Diseases, China Medical University Children’s Hospital, China Medical University, Taichung, Taiwan
3School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui-Kai Kuo
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Be-Sheng Kuo
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hope Liu
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuo-Liang Hou
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan-Yu Tsai
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han-Chen Chiu
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Hsin Ho
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Cheng
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min-Sheng Wang
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ya-Ting Yang
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Po-Yen Chang
1UBI Asia, Hsinchu, Taiwan
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yea-Huei Shen
4StatPlus, Inc., Taipei, Taiwan
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Jiun Peng
1UBI Asia, Hsinchu, Taiwan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance The SARS-CoV-2 non-spike structural proteins of nucleocapsid (N), membrane (M) and envelope (E) are critical in the host cell interferon response and memory T-cell immunity and have been grossly overlooked in the development of COVID vaccines.

Objective To determine the safety and immunogenicity of UB-612, a multitope vaccine containing S1-RBD-sFc protein and rationally-designed promiscuous peptides representing sequence-conserved Th and CTL epitopes on the Sarbecovirus nucleocapsid (N), membrane (M) and spike (S2) proteins.

Design, setting and participants UB-612 booster vaccination was conducted in Taiwan. A UB-612 booster dose was administered 6-8 months post-2nd dose in 1,478 vaccinees from 3,844 healthy participants (aged 18-85 years) who completed a prior placebo (saline)-controlled, randomized, observer-blind, multi-center Phase-2 primary 2-dose series (100-μg per dose; 28-day apart) of UB-612. The interim safety and immunogenicity were evaluated until 14 days post-booster.

Exposure Vaccination with a booster 3rd-dose (100-μg) of UB-612 vaccine.

Main outcomes and measures Solicited local and systemic AEs were recorded for seven days in the e-diaries of study participants, while skin allergic reactions were recorded for fourteen days. The primary immunogenicity endpoints included viral-neutralizing antibodies against live SARS-CoV-2 wild-type (WT, Wuhan strain) and live Delta variant (VNT50), and against pseudovirus WT and Omicron variant (pVNT50). The secondary immunogenicity endpoints included anti-S1-RBD IgG antibody, S1-RBD:ACE2 binding inhibition, and T-cell responses by ELISpot and Intracellular Staining.

Results No post-booster vaccine-related serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, mostly mild and transient. The UB-612 booster prompted a striking upsurge of neutralizing antibodies against live WT Wuhan strain (VNT50, 1,711) associated with unusually high cross-neutralization against Delta variant (VNT50, 1,282); and similarly with a strong effect against pseudovirus WT (pVNT50, 6,245) and Omicron variant (pVNT50, 1,196). Upon boosting, the lower VNT50 and pVNT50 titers of the elderly in the primary series were uplifted to the same levels as those of the young adults. The UB-612 also induced robust, durable VoC antigen-specific Th1-oriented (IFN-γ+-) responses along with CD8+ T-cell (CD107a+-Granzyme B+) cytotoxicity.

Conclusions and relevance With a pronounced cross-reactive booster effect on B- and T-cell immunity, UB-612 may serve as a universal vaccine booster for comprehensive immunity enhancement against emergent VoCs.

Trial registration [ClinicalTrials.gov: NCT04773067]

Question Facing ever-emergent SARS-CoV-2 variants and long-haul COVID, can composition-updated new vaccines be constructed capable of inducing striking, durable booster-recalled B/T-immunity to prevent infection by VoCs?

Findings In a Phase-2 extension study, a booster dose of UB-612 multitope protein-peptide vaccine prompted high viral-neutralizing titers against live wild-type virus (VNT50, 1,711), Delta variant (VNT50, 1,282); pseudovirus wild-type (pVNT50, 6,245) and Omicron variant (pVNT50, 1,196). Robust, durable Th1-IFNγ+ responses and CD8+ T cell-(CD107a+-Granzyme B+) cytotoxic activity were both observed.

Meaning UB-612 RBD-sFc vaccine armed with T cell immunity-promoting conserved N, M and S2 Th/CTL epitope peptides may serve as a universal vaccine to fend off new VoCs.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04773067

Funding Statement

UBI Asia (study sponsor) and the Taiwan Centers for Disease Control, Ministry of Health and Welfare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted at China Medical University Hospital, Taiwan; the Institutional Review Board of the study site and the Taiwan Food and Drug Administration approved the design of the study and the contents of the informed consent form and openly available at these sites.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

https://unitedbiomedical.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
Chang Yi Wang, Kao-Pin Hwang, Hui-Kai Kuo, Be-Sheng Kuo, Hope Liu, Kuo-Liang Hou, Wan-Yu Tsai, Han-Chen Chiu, Yu-Hsin Ho, Jennifer Cheng, Min-Sheng Wang, Ya-Ting Yang, Po-Yen Chang, Yea-Huei Shen, Wen-Jiun Peng
medRxiv 2022.04.11.22272364; doi: https://doi.org/10.1101/2022.04.11.22272364
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
Chang Yi Wang, Kao-Pin Hwang, Hui-Kai Kuo, Be-Sheng Kuo, Hope Liu, Kuo-Liang Hou, Wan-Yu Tsai, Han-Chen Chiu, Yu-Hsin Ho, Jennifer Cheng, Min-Sheng Wang, Ya-Ting Yang, Po-Yen Chang, Yea-Huei Shen, Wen-Jiun Peng
medRxiv 2022.04.11.22272364; doi: https://doi.org/10.1101/2022.04.11.22272364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (755)
  • Anesthesia (221)
  • Cardiovascular Medicine (3288)
  • Dentistry and Oral Medicine (364)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13360)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5147)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3264)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14622)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (127)
  • Nephrology (522)
  • Neurology (4919)
  • Nursing (262)
  • Nutrition (727)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2519)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4205)
  • Public and Global Health (7500)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1011)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)